Teligent

Teligent develop, manufacture and market pharmaceutical products for use by doctors and patients in the United States and Canada.  They are a dynamic group of about 130 employees based in New Jersey, Toronto, Montreal and Tallinn, Estonia. Their Product Development and Manufacturing complex is in Buena, New Jersey, approximately 45 minutes from Philadelphia. In 2015 They acquired Alveda Pharmaceuticals Inc., a Toronto-based pharmaceutical company focused on the Canadian injectable pharmaceutical market. In 2016 They hired Their first European colleagues in Tallinn who support Their supply chain and quality operations.

VJGJ, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over the counter, and cosmetic markets. The company was founded by Jane E. Hager on August 26, 1977 and is headquartered in Buena, NJ.

The stock price of Teligent Inc (NASDAQ: TLGT) fell over 39% yesterday. This is why it happened.

TLGT Stock: Why The Price Substantially Fell

BUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company.

Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

Micronet Enertec Technologies

New Gold

Are these top penny stocks to watch on your list in September? The post Top Penny Stocks to Buy Right Now?

Top Penny Stocks to Buy Right Now? 3 to Check Out This Month

PHILADELPHIA--(BUSINESS WIRE)--If you purchased or acquired Teligent common stock from March 7, 2017 to November 6, 2017, your rights will be affected by a settlement.

Scott+Scott Attorneys at Law LLP Announces a Notice of Proposed Settlement of Class Action for the Teligent, Inc. Securities Class Action

Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2021 Results - Earnings Call Transcript

BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update.

Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

Scheduled to Reconvene on July 21, 2021 Company Urgently Encourages Stockholders to Vote

Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders

Jaguar Health

Seelos Therapeutics

Biotech penny stocks are heating up as Covid cases decline; which small-caps are on your watchlist? The post Trading Biotech Penny Stocks?

Trading Biotech Penny Stocks? Check These 3 Out

Teligent's (TLGT) CEO Tim Sawyer on Q1 2021 Results - Earnings Call Transcript

Shares of Teligent (NASDAQ:TLGT) rose 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 13.04% year over year to ($0.26), which may not compare to the estimate of ($2.11).

Teligent: Q1 Earnings Insights

BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update.

Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update

BUENA, N.J., May 21, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Tuesday, May 25th, 2021 to discuss the first quarter ended March 31, 2021 financial results and business update.

Teligent, Inc. to Hold Conference Call for First Quarter 2021 Financial Results on Tuesday May 25, 2020

BUENA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2020.

Teligent, Inc. Announces 2020 Year-End Earnings Report and Provides Business Update

BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021.

Teligent Announces Hiring of Chief Financial Officer

BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the...

Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors

BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr....

Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors

BUENA, N.J., Jan. 28, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced a series of strategic actions in partnership with its senior lenders and its Series C noteholders to...

Teligent Takes Strategic Steps to Recapitalize and Position Business for Success

BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission. Upon filing of the Form 10-Q on December 31, 2020, the Company regained compliance with Nasdaq Listing Rule 5250(c)(1) and this matter is now closed.

Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule

BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.

Teligent, Inc. Announces Third Quarter 2020 Results

Shares of TLGT stock are soaring on Monday ahead of a special shareholder vote to address Teligent's Nasdaq compliance. The post Teligent: 7 Things for Investors to Know About TLGT Stock appeared first on InvestorPlace.

Teligent: 7 Things for Investors to Know About TLGT Stock

Scheduled to Reconvene on December 16 , 2020 Company Urgently Encourages Stockholders to Vote

Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders

LOS ANGELES--(BUSINESS WIRE)---- $TLGT #TLGT--TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc.

TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses to Contact the Firm

BUENA, N.J., Sept.  23, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible Senior Notes due 2023 (the “New 2023 Notes”) in exchange for approximately $57.9 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 4.75% Convertible Senior Notes due May 2023 (the “Series A Convertible Notes”), which gives effect to a 52.5% discount on the principal amount of Series A Convertible Notes exchanged. The Company also issued approximately $0.4 million aggregate principal amount of New 2023 Notes in exchange for approximately $0.5 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 7.0% Cash / 8.0% PIK Series B Senior Unsecured Convertible Notes due 2023 (the “Series B Convertible Notes”), which gives effect to a 31% discount on the principal amount of Series B Convertible Notes exchanged.

Teligent Announces Completion of Series D Convertible Note Exchange

Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2020 Results - Earnings Call Transcript

BUENA, N.J., Aug.  19, 2020  (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2020.

News for Teligent Stock (TLGT)